within Pharmacolibrary.Drugs.ATC.A;

model A02BA03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.4,
    Cl             = 0.006883333333333333,
    adminDuration  = 600,
    adminMass      = 40 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0011,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.019,
    Tlag           = 12.0
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A02BA03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Famotidine is a histamine H2 receptor antagonist used to reduce stomach acid production. It is commonly indicated for the treatment of peptic ulcer disease, gastroesophageal reflux disease (GERD), and conditions that cause excessive stomach acid such as Zollinger-Ellison syndrome. Famotidine is approved and widely used today both as a prescription and over-the-counter medication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after a single 40 mg oral dose.</p><h4>References</h4><ol><li><p>Upreti, VV, et al., &amp; Frost, CE (2013). Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. <i>Clinical pharmacology : advances and applications</i> 5 59–66. DOI:<a href=&quot;https://doi.org/10.2147/CPAA.S41999&quot;>10.2147/CPAA.S41999</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23637566/&quot;>https://pubmed.ncbi.nlm.nih.gov/23637566</a></p></li><li><p>Gotoh, Y, et al., &amp; Suzuki, T (2023). Yoghurt as a deglutition aid for oral medication: effects on famotidine powder dissolution rate and pharmacokinetics. <i>Scientific reports</i> 13(1) 1993–None. DOI:<a href=&quot;https://doi.org/10.1038/s41598-023-29258-9&quot;>10.1038/s41598-023-29258-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36737669/&quot;>https://pubmed.ncbi.nlm.nih.gov/36737669</a></p></li><li><p>Echizen, H, &amp; Ishizaki, T (1991). Clinical pharmacokinetics of famotidine. <i>Clinical pharmacokinetics</i> 21(3) 178–194. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199121030-00003&quot;>10.2165/00003088-199121030-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1764869/&quot;>https://pubmed.ncbi.nlm.nih.gov/1764869</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A02BA03;
